Exelixis Inc (NASDAQ:EXEL) — Market Cap & Net Worth
Market Cap & Net Worth: Exelixis Inc (EXEL)
Exelixis Inc (NASDAQ:EXEL) has a market capitalization of $12.17 Billion ($12.17 Billion) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1951 globally and #723 in its home market, demonstrating a 0.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Exelixis Inc's stock price $53.00 by its total outstanding shares 259708689 (259.71 Million). Review debt load of Exelixis Inc to assess the company's total debt and financial obligations.
Exelixis Inc Market Cap History: 2015 to 2026
Exelixis Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.46 Billion to $13.76 Billion (23.06% CAGR).
Index Memberships
Exelixis Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$918.18 Billion | 1.33% | #18 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.50% | #34 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.03% | #221 of 3165 |
|
S&P Midcap 400
MID
|
$3.56 Trillion | 0.38% | #76 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.72% | #26 of 263 |
Weight: Exelixis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Exelixis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Exelixis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.91x
Exelixis Inc's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.55x
Exelixis Inc's market cap is 14.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.87 Billion | $191.45 Million | -$70.22 Million | 20.23x | N/A |
| 2017 | $7.90 Billion | $452.48 Million | $154.23 Million | 17.45x | 51.19x |
| 2018 | $5.11 Billion | $853.83 Million | $690.07 Million | 5.98x | 7.40x |
| 2019 | $4.58 Billion | $967.77 Million | $321.01 Million | 4.73x | 14.26x |
| 2020 | $5.21 Billion | $987.54 Million | $111.78 Million | 5.28x | 46.63x |
| 2021 | $4.75 Billion | $1.43 Billion | $231.06 Million | 3.31x | 20.55x |
| 2022 | $4.17 Billion | $1.61 Billion | $182.28 Million | 2.59x | 22.85x |
| 2023 | $6.23 Billion | $1.83 Billion | $207.76 Million | 3.40x | 29.99x |
| 2024 | $8.65 Billion | $2.17 Billion | $521.27 Million | 3.99x | 16.59x |
| 2025 | $11.38 Billion | $2.32 Billion | $782.57 Million | 4.91x | 14.55x |
Competitor Companies of EXEL by Market Capitalization
Companies near Exelixis Inc in the global market cap rankings as of June 16, 2026.
Key companies related to Exelixis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Exelixis Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Exelixis Inc's market cap moved from $1.46 Billion to $ 13.76 Billion, with a yearly change of 23.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.76 Billion | +20.92% |
| 2025 | $11.38 Billion | +31.62% |
| 2024 | $8.65 Billion | +38.81% |
| 2023 | $6.23 Billion | +49.56% |
| 2022 | $4.17 Billion | -12.25% |
| 2021 | $4.75 Billion | -8.92% |
| 2020 | $5.21 Billion | +13.90% |
| 2019 | $4.58 Billion | -10.42% |
| 2018 | $5.11 Billion | -35.30% |
| 2017 | $7.90 Billion | +103.89% |
| 2016 | $3.87 Billion | +164.36% |
| 2015 | $1.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Exelixis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.17 Billion USD |
| MoneyControl | $12.17 Billion USD |
| MarketWatch | $12.17 Billion USD |
| marketcap.company | $12.17 Billion USD |
| Reuters | $12.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyro… Read more